The famous — and arguably, infamous — HeLa cervical cancer cell line was first cultivated in 1952. Barely six years later, scientists learned that human cell cultures could be invaded by both ...

Cervical cancer deaths have dropped due to better screening, but fewer women are keeping up with tests. An AXA Health ...

Cervical cancer remains one of the most challenging diseases in oncology, with high recurrence rates and significant treatment side effects. For decades, the standard approach has relied on a ...

Several studies have been carried out by following this approach and contribute to broaden the knowledge on the transforming mechanisms crucial for cervical cancer development. Ku70BP and HSP60 ...

Keytruda is already approved by the FDA as a first-line therapy for PD-L1-positive metastatic cervical cancer in combination ... include its takeover of T-cell engager developer Harpoon ...

A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating advanced cervical cancer ... months for third-line treatments.

It effectively targets human breast and cervical cancer cell lines. Known as tulsi in Ayurveda, basil contains eugenol, apigenin, and rosmarinic acid, which help combat skin, oral, liver ...

for use on the National Health Service as a second-line monotherapy treatment for adults with recurrent or metastatic cervical cancer and disease progression on or after platinum-based ...

By binding to PD-1 cemiplimab has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. The SMC’s acceptance is based on data from the EMPOWER-Cervical 1 phase 3 ...